Published in Bull Cancer on January 01, 2006
Angiosarcomas and taxanes. Curr Treat Options Oncol (2007) 1.29
Synthesis, antitumor activity, and mechanism of action of benzo[a]pyrano[3,2-h]acridin-7-one analogues of acronycine. J Med Chem (2006) 1.12
Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem (2005) 1.06
Design of DNA minor groove binding diamidines that recognize GC base pair sequences: a dimeric-hinge interaction motif. J Am Chem Soc (2007) 1.02
Selective inhibition of topoisomerase I and various steps of spliceosome assembly by diospyrin derivatives. Mol Pharmacol (2004) 0.99
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol (2011) 0.99
Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux. Cancer Lett (2005) 0.95
Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res (2004) 0.92
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res (2008) 0.89
Alkaloids from Cassytha filiformis and related aporphines: antitrypanosomal activity, cytotoxicity, and interaction with DNA and topoisomerases. Planta Med (2004) 0.89
Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorg Med Chem (2008) 0.86
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol (2010) 0.85
Generation of replication-dependent double-strand breaks by the novel N2-G-alkylator S23906-1. Cancer Res (2006) 0.84
Covalent binding of antitumor benzoacronycines to double-stranded DNA induces helix opening and the formation of single-stranded DNA: unique consequences of a novel DNA-bonding mechanism. Mol Cancer Ther (2005) 0.83
Induction of apoptosis by the plant alkaloid sampangine in human HL-60 leukemia cells is mediated by reactive oxygen species. Eur J Pharmacol (2005) 0.83
Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine. Biochemistry (2002) 0.82
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. Target Oncol (2013) 0.82
Molecular determinants for DNA minor groove recognition: design of a bis-guanidinium derivative of ethidium that is highly selective for AT-rich DNA sequences. Biochemistry (2005) 0.82
Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1. Biochem Pharmacol (2002) 0.82
Synthesis and cytotoxic activity of benzo[c][1,7] and [1,8]phenanthrolines analogues of nitidine and fagaronine. Bioorg Med Chem (2004) 0.82
Design of a composite ethidium-netropsin-anilinoacridine molecule for DNA recognition. Chembiochem (2003) 0.81
Synthesis and biological activities of new furo[3,4-b]carbazoles: potential topoisomerase II inhibitors. Eur J Med Chem (2010) 0.81
Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates. Mol Cell Biol (2006) 0.81
Synthesis and biological evaluation of novel phenylcarbazoles as potential anticancer agents. J Med Chem (2006) 0.81
[Gemcitabine: from preclinic to clinic passing by pharmacokinetics]. Bull Cancer (2007) 0.81
Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties. Bioorg Med Chem (2010) 0.80
Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives. Eur J Med Chem (2009) 0.80
Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives. J Med Chem (2008) 0.80
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth. Eur J Pharm Sci (2011) 0.79
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res (2009) 0.79
Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides. Biochemistry (2003) 0.78
Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan. Bioconjug Chem (2009) 0.78
Amino- and glycoconjugates of pyrido[4,3,2-kl]acridine. Synthesis, antitumor activity, and DNA binding. Bioorg Med Chem (2006) 0.78
Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction. Anticancer Drugs (2013) 0.78
Activity of the polyamine-vectorized anti-cancer drug F14512 against pediatric glioma and neuroblastoma cell lines. Invest New Drugs (2014) 0.78
Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials. Invest New Drugs (2009) 0.77
Synthesis of 2,5- and 3,5-diphenylpyridine derivatives for DNA recognition and cytotoxicity. Eur J Med Chem (2005) 0.77
Synthesis, antiproliferative activity and tubulin targeting effect of acridinone and dioxophenothiazine derivatives. Eur J Med Chem (2012) 0.77
Targeting DNA with novel diphenylcarbazoles. Biochemistry (2004) 0.77
[The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology]. Bull Cancer (2011) 0.77
Synthesis, antitumor activity, and mechanism of action of benzo[b]chromeno[6,5-g][1,8]naphthyridin-7-one analogs of acronycine. J Med Chem (2014) 0.77
Montmorillonite K-10 catalyzed cyclization of N-ethoxycarbonyl-N'-arylguanidines: access to pyrimido[4,5-c]carbazole and pyrimido[5,4-b]indole derivatives. Bioorg Med Chem Lett (2010) 0.76
New selective carbonic anhydrase IX inhibitors: synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides. Bioorg Med Chem (2012) 0.76
[Molecular determinants of response to topoisomerase I inhibitors]. Bull Cancer (2011) 0.76
Oxoazabenzo[de]anthracenes conjugated to amino acids: synthesis and evaluation as DNA-binding antitumor agents. Bioconjug Chem (2005) 0.75
Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives. J Med Chem (2010) 0.75
Synthesis and biological evaluation of novel oxophenylarcyriaflavins as potential anticancer agents. Org Biomol Chem (2008) 0.75
Synthesis of 2,6-diphenylpyrazine derivatives and their DNA binding and cytotoxic properties. Eur J Med Chem (2005) 0.75
Unusual cellular uptake of cytotoxic 4-hydroxymethyl-3-aminoacridine. Eur J Med Chem (2009) 0.75
Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd(0) catalysed reductive N-heteroannulation. Org Biomol Chem (2010) 0.75
Synthesis, cytotoxic activity, and DNA binding properties of antitumor cis-1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine cinnamoyl esters. Bioorg Med Chem (2009) 0.75
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones. Bioorg Med Chem Lett (2011) 0.75
Chiral capillary electrophoretic determination of the enantiomeric purity of homocamptothecin derivatives, promising antitumor topoisomerase I inhibitors, using highly sulfated CDs and fluorescence detection. Electrophoresis (2006) 0.75
Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II. Biochem Pharmacol (2004) 0.75
4-Hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents. J Med Chem (2003) 0.75
[Methodological approaches of clinical studies with targeted therapies]. Bull Cancer (2008) 0.75